Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12745983 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL1463970 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL1463973 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL1463939 | 0.83 | KMT2A (0.45) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL1463937 | 0.83 | KMT2A (0.45) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL9782112 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL15803677 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL3998923 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL12745999 | 0.75 | ALDH1A1 (0.44) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL7944901 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2260041-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009148654-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | ALDH1A1 1109/4885KMT2A 1633/4885TDP1 2188/4885 |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | ALDH1A1 1109/4885KMT2A 1633/4885TDP1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.